463 related articles for article (PubMed ID: 18322974)
1. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
[TBL] [Abstract][Full Text] [Related]
4. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
5. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
[TBL] [Abstract][Full Text] [Related]
6. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
[TBL] [Abstract][Full Text] [Related]
8. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
[TBL] [Abstract][Full Text] [Related]
11. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Us D; Gülmez D; Hasçelik G
Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
Bobbio-Pallavicini F; Alpini C; Caporali R; Avalle S; Bugatti S; Montecucco C
Arthritis Res Ther; 2004; 6(3):R264-72. PubMed ID: 15142273
[TBL] [Abstract][Full Text] [Related]
13. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
[TBL] [Abstract][Full Text] [Related]
14. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy.
de Man YA; Bakker-Jonges LE; Goorbergh CM; Tillemans SP; Hooijkaas H; Hazes JM; Dolhain RJ
Ann Rheum Dis; 2010 Feb; 69(2):420-3. PubMed ID: 19282308
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
Sihvonen S; Korpela M; Mustila A; Mustonen J
J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
[TBL] [Abstract][Full Text] [Related]
16. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
[TBL] [Abstract][Full Text] [Related]
18. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients.
García-Berrocal B; González C; Pérez M; Navajo JA; Moreta I; Dávila C; González-Buitrago JM
Clin Chim Acta; 2005 Apr; 354(1-2):123-30. PubMed ID: 15748608
[TBL] [Abstract][Full Text] [Related]
19. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
20. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]